Quanterix
Edit

Quanterix

https://www.quanterix.com/
Last activity: 15.07.2026
Active
Categories: AnalyticsAutomationDiagnosticsHealthTechLifePlatformResearchScienceTechnologyTools
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Likes
797
Followers
1.28K
Followers
8.31K
Website visits
23.7K /mo.
Mentions
57
Location: United States, Massachusetts, Billerica
Employees: 201-500
Phone: +1 617-301-9400
Total raised: $128.7M
Founded date: 2007

Investors 4

Funding Rounds 5

DateSeriesAmountInvestors
04.06.2019-$49.7M-
03.08.2017-$8.5M-
23.03.2016Series D$46M-
15.11.2012Series C$18.5M-
20.08.2011-$6M-

Mentions in press and media 57

DateTitleDescription
15.07.2026Tau Therapy Slows Alzheimer’s Decline in First Human Trial as AAIC 2026 Wraps in LondonBy Ronald Holman Published: Jul 15 2026, 11:50 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
04.02.2026Boomband Raises $4.0M in Seed FundingBoomband, a Charlestown, RI-based AI-native talent marketplace, raised $4.0M in Seed funding. The round was led by Boston Seed with participation from New England VC’s Slater Technology Fund, Rogue Venture Partners and Service Provider Capi...
03.11.2025Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s DiseaseArctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease Mon, Nov 03, 2025 07:00 CET Report this content The European Medicines Agency (EMA) authorises initiation of a Phase IIa study evaluating AT-001 ...
09.07.2025Quanterix Completes Acquisition Of Akoya BiosciencesQuanterix Corporation (NASDAQ: QTRX), a Billerica, MA-based company improving scientific discovery through ultra-sensitive biomarker detection, announced that it has completed its previously announced acquisition of Akoya Biosciences, a Mar...
05.03.2025Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent DirectorROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of...
05.09.2024A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in ChinaSHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in ...
23.04.2024Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales OrganizationCapitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization Tue, Apr 23, 2024 07:52 CET Report this content Capitainer, a leading Swedish medtech company that specializes in user-friendly self-sampling soluti...
03.04.2024A Goldman Sachs research director explains how he created the firm's best-of-the-best stock-pick list — and makes the case for 22 top companies with up to 59% upsideMarkets A Goldman Sachs research director explains how he created the firm's best-of-the-best stock-pick list — and makes the case for 22 top companies with up to 59% upside James Faris 2024-04-03T08:30:02Z Share icon An curved arrow pointi...
11.03.2024Neurological Biomarkers Market 2024 Global Analysis: Insights, Size, Share |Athena Diagnostics, Psynova NeurotechNeurological Biomarkers Market Neurological biomarkers are detectable substances majorly found in the cerebrospinal (CSF) fluid when there has been some damage to the brain. BURLINGAME, CALIFORNIA , UNITED STATES, March 11, 2024 /EINPresswi...
20.02.2024Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefitMelody Petersen | Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In